A differential change between E+P and E-alone in IGFBP1 was supported by ELISA data in an independent set of 50 subjects for each regimen (Figure 2) and may provide an important lead to understanding clinical effects that differ between the two preparations, including breast cancer. Here, IGFBP1 is linked to breast carcinoma.